Goldman Sachs Invests US$20 Million in Ascletis

Dr. Jinzi Wu was Invited to Speak at 11th Annual Gates Foundation Grand Challenges Conference

Ascletis Secures US$35 Million Financing

Ascletis Initiates Phase II Clinical Trial of Its Interferon-Free HCV Regimen in Taiwan

Ascletis as the First Chinese Company to File Clinical Applications for Interferon-Free HCV Treatment